Sign in or create an account to add this stock to your watchlist.
About REGENXBIO (NASDAQ:RGNX)
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration. It is also developing RGX-501 for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111 to treat the neurological symptoms of Mucopolysaccharidosis Type I that uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system (CNS). In addition, the company engages in the development of RGX-121 for the treatment of neurological symptoms of Mucopolysaccharidosis Type II, which uses the AAV9 vector to deliver the human iduronate-2-sulfatase gene to the CNS. Further, it licenses its NAV technology platform to other biotechnology companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RGNX
CUSIPN/A
Phone240-552-8181
Debt
Debt-to-Equity RatioN/A
Current Ratio17.67
Quick Ratio17.67
Price-To-Earnings
Trailing P/E Ratio-19.88
Forward P/E Ratio79.84
P/E Growth26.05
Sales & Book Value
Annual Sales$10.39 million
Price / Sales149.71
Cash FlowN/A
Price / CashN/A
Book Value$9.37 per share
Price / Book5.20
Profitability
EPS (Most Recent Fiscal Year)($2.45)
Net Income$-73,160,000.00
Net Margins37.28%
Return on Equity23.27%
Return on Assets21.78%
Miscellaneous
Employees139
Outstanding Shares31,940,000
REGENXBIO (NASDAQ:RGNX) Frequently Asked Questions
What is REGENXBIO's stock symbol?
REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."
How were REGENXBIO's earnings last quarter?
REGENXBIO Inc. (NASDAQ:RGNX) posted its earnings results on Tuesday, May, 8th. The biotechnology company reported $3.04 earnings per share for the quarter, topping analysts' consensus estimates of $1.00 by $2.04. The biotechnology company earned $132.39 million during the quarter, compared to analyst estimates of $80 million. REGENXBIO had a return on equity of 23.27% and a net margin of 37.28%. View REGENXBIO's Earnings History.
When is REGENXBIO's next earnings date?
What price target have analysts set for RGNX?
7 analysts have issued 1 year target prices for REGENXBIO's shares. Their predictions range from $25.00 to $90.00. On average, they expect REGENXBIO's stock price to reach $44.1429 in the next year. View Analyst Ratings for REGENXBIO.
What are Wall Street analysts saying about REGENXBIO stock?
Here are some recent quotes from research analysts about REGENXBIO stock:
- 1. According to Zacks Investment Research, "REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland. " (4/17/2018)
- 2. Chardan Capital analysts commented, "We have long highlighted the importance of vector science for the progress in GT; and, we see Commissioner Gottlieb’s comments as highly supportive of our views. We again highlight REGENXBIO (Buy) (a Chardan Top Pick for 2017, and our Gene Therapy Top Pick) as the best way to play the emergence of in vivo GT, due to the company’s: (1) rights to 100+ vectors, (2) partnerships with 10 companies, (3) 25 or so internal and external product candidates, over 10 of which are in clinical development, and (4) abundance of important 2017 catalysts, which to us represent upside options." (12/11/2017)
Who are some of REGENXBIO's key competitors?
Some companies that are related to REGENXBIO include Bio-Techne (TECH), CRISPR Therapeutics (CRSP), arGEN-X BV (ARGX), Spark Therapeutics (ONCE), Halozyme (HALO), China Biologic Products (CBPO), Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Repligen (RGEN), Momenta Pharmaceuticals (MNTA), Editas Medicine (EDIT), Acceleron Pharma (XLRN), Sangamo Therapeutics (SGMO) and Iovance Biotherapeutics (IOVA).
Who are REGENXBIO's key executives?
REGENXBIO's management team includes the folowing people:
- Mr. Kenneth T. Mills, CEO, Pres & Director (Age 43)
- Mr. Curran M. Simpson, Sr. VP of Technical Operations (Age 56)
- Mr. Vittal K. Vasista, CFO & Principal Accounting Officer (Age 50)
- Mr. Patrick J. Christmas II, Sr. VP & Gen. Counsel (Age 47)
- Mr. Andrew Yost, VP of Corp. Devel.
Has REGENXBIO been receiving favorable news coverage?
News stories about RGNX stock have been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. REGENXBIO earned a media sentiment score of 0.05 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 45.13 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are REGENXBIO's major shareholders?
REGENXBIO's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.97%), Redmile Group LLC (6.67%), Franklin Resources Inc. (2.41%), Millennium Management LLC (0.72%), Botty Investors LLC (0.63%) and WS Management Lllp (0.63%). Company insiders that own REGENXBIO stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Institutional Ownership Trends for REGENXBIO.
Which major investors are selling REGENXBIO stock?
RGNX stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Millennium Management LLC, BlackRock Inc., Wells Fargo & Company MN, Legal & General Group Plc and California State Teachers Retirement System. Company insiders that have sold REGENXBIO company stock in the last year include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Insider Buying and Selling for REGENXBIO.
Which major investors are buying REGENXBIO stock?
RGNX stock was acquired by a variety of institutional investors in the last quarter, including Redmile Group LLC, WS Management Lllp, Sphera Funds Management LTD., A.R.T. Advisors LLC, Altrinsic Global Advisors LLC, Allianz Asset Management GmbH, Highbridge Capital Management LLC and UBS Group AG. View Insider Buying and Selling for REGENXBIO.
How do I buy shares of REGENXBIO?
Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is REGENXBIO's stock price today?
One share of RGNX stock can currently be purchased for approximately $48.70.
How big of a company is REGENXBIO?
REGENXBIO has a market capitalization of $1.56 billion and generates $10.39 million in revenue each year. The biotechnology company earns $-73,160,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis. REGENXBIO employs 139 workers across the globe.
How can I contact REGENXBIO?
REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]
MarketBeat Community Rating for REGENXBIO (RGNX)
MarketBeat's community ratings are surveys of what our community members think about REGENXBIO and other stocks. Vote "Outperform" if you believe RGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
REGENXBIO (NASDAQ:RGNX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for REGENXBIO in the last 12 months. Their average twelve-month price target is $44.1429, suggesting that the stock has a possible downside of 9.36%. The high price target for RGNX is $90.00 and the low price target for RGNX is $25.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.86 | 2.86 | 2.86 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $44.1429 | $42.7143 | $41.00 | $44.20 |
| Price Target Upside: | 9.36% downside | 22.04% upside | 53.27% upside | 67.74% upside |
REGENXBIO (NASDAQ:RGNX) Consensus Price Target History
REGENXBIO (NASDAQ:RGNX) Analyst Ratings History
Show:
(Data available from 5/20/2016 forward)
REGENXBIO (NASDAQ:RGNX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
REGENXBIO (NASDAQ RGNX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 16.90%
Institutional Ownership Percentage: 67.42%
REGENXBIO (NASDAQ RGNX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/15/2018 | Donald J Hayden Jr | Director | Sell | 15,000 | $50.05 | $750,750.00 | |  |
| 5/15/2018 | Vittal Vasista | CFO | Sell | 7,500 | $50.10 | $375,750.00 | | |
| 4/20/2018 | Kenneth T Mills | Insider | Sell | 10,000 | $39.52 | $395,200.00 | 219,430 | |
| 4/16/2018 | Vittal Vasista | CFO | Sell | 5,000 | $37.56 | $187,800.00 | 154,434 | |
| 4/11/2018 | Patrick J Christmas | SVP | Sell | 10,000 | $39.00 | $390,000.00 | 11,141 | |
| 4/9/2018 | Patrick J Christmas | SVP | Sell | 10,000 | $34.00 | $340,000.00 | 11,141 | |
| 3/26/2018 | Vittal Vasista | CFO | Sell | 5,000 | $30.00 | $150,000.00 | 157,283 | |
| 3/20/2018 | Kenneth T Mills | Insider | Sell | 10,000 | $29.55 | $295,500.00 | 228,530 | |
| 3/13/2018 | Curran Simpson | SVP | Sell | 25,000 | $33.00 | $825,000.00 | | |
| 2/20/2018 | Kenneth T Mills | Insider | Sell | 10,000 | $26.56 | $265,600.00 | 238,530 | |
| 1/22/2018 | Kenneth T Mills | Insider | Sell | 10,000 | $27.33 | $273,300.00 | 248,530 | |
| 1/16/2018 | Vittal Vasista | CFO | Sell | 5,000 | $30.16 | $150,800.00 | | |
| 12/22/2017 | Curran Simpson | SVP | Sell | 30,000 | $33.03 | $990,900.00 | 69,500 | |
| 12/20/2017 | Kenneth T Mills | Insider | Sell | 10,000 | $31.75 | $317,500.00 | 108,530 | |
| 12/19/2017 | Vittal Vasista | CFO | Sell | 5,000 | $30.00 | $150,000.00 | 87,277 | |
| 12/7/2017 | Curran Simpson | SVP | Sell | 21,890 | $30.04 | $657,575.60 | 41,390 | |
| 12/4/2017 | Curran Simpson | SVP | Sell | 110 | $30.00 | $3,300.00 | 39,610 | |
| 11/27/2017 | Curran Simpson | SVP | Sell | 2,000 | $29.31 | $58,620.00 | 41,500 | |
| 11/20/2017 | Kenneth T Mills | Insider | Sell | 10,000 | $27.71 | $277,100.00 | | |
| 10/20/2017 | Kenneth T Mills | Insider | Sell | 10,000 | $32.62 | $326,200.00 | 98,730 | |
| 10/16/2017 | Vittal Vasista | CFO | Sell | 5,000 | $33.25 | $166,250.00 | 92,283 | |
| 10/11/2017 | Donald J Hayden Jr | Director | Sell | 20,000 | $34.95 | $699,000.00 | | |
| 9/27/2017 | Donald J Hayden Jr | Director | Sell | 20,000 | $32.45 | $649,000.00 | 20,000 | |
| 9/20/2017 | Kenneth T Mills | Insider | Sell | 10,000 | $29.33 | $293,300.00 | 108,630 | |
| 9/18/2017 | Donald J Hayden Jr | Director | Sell | 40,000 | $28.70 | $1,148,000.00 | 20,000 | |
| 9/15/2017 | Vittal Vasista | CFO | Sell | 5,000 | $27.39 | $136,950.00 | 99,594 | |
| 9/8/2017 | Stephen Yoo | Insider | Sell | 27,342 | $25.00 | $683,550.00 | 27,342 | |
| 9/6/2017 | Stephen Yoo | Insider | Sell | 32,658 | $25.00 | $816,450.00 | 31,803 | |
| 9/5/2017 | Donald J Hayden Jr | Director | Sell | 20,000 | $24.95 | $499,000.00 | 20,000 | |
| 9/5/2017 | Kenneth T Mills | Insider | Sell | 10,500 | $25.00 | $262,500.00 | 118,530 | |
| 8/21/2017 | Kenneth T Mills | Insider | Sell | 6,500 | $20.05 | $130,325.00 | 105,500 | |
| 8/15/2017 | Vittal Vasista | CFO | Sell | 3,040 | $21.09 | $64,113.60 | 103,118 | |
| 7/20/2017 | Kenneth T Mills | Insider | Sell | 6,500 | $18.66 | $121,290.00 | 112,000 | |
| 7/17/2017 | Vittal Vasista | CFO | Sell | 3,100 | $19.81 | $61,411.00 | 108,423 | |
| 6/20/2017 | Kenneth T Mills | Insider | Sell | 6,500 | $19.68 | $127,920.00 | 119,396 | |
| 6/15/2017 | Vittal Vasista | CFO | Sell | 3,100 | $18.75 | $58,125.00 | 107,512 | |
| 4/24/2017 | Donald J Hayden Jr | Director | Sell | 10,000 | $20.98 | $209,800.00 | 28,599 | |
| 4/24/2017 | Kenneth T Mills | Insider | Sell | 15,440 | $20.98 | $323,931.20 | 126,395 | |
| 4/24/2017 | Vittal Vasista | CFO | Sell | 3,100 | $21.00 | $65,100.00 | 114,039 | |
| 5/17/2016 | Fmr Llc | Insider | Sell | 18,300 | $12.41 | $227,103.00 | | |
| 5/16/2016 | Fmr Llc | Insider | Sell | 16,030 | $11.65 | $186,749.50 | | |
| 5/12/2016 | Fmr Llc | Insider | Sell | 6,711 | $10.85 | $72,814.35 | | |
| 5/11/2016 | Fmr Llc | Insider | Sell | 25,132 | $10.36 | $260,367.52 | | |
| 5/9/2016 | Fmr Llc | Insider | Sell | 10,570 | $9.94 | $105,065.80 | | |
| 5/4/2016 | Fmr Llc | Insider | Sell | 1,896 | $10.51 | $19,926.96 | | |
| 5/3/2016 | Fmr Llc | Insider | Sell | 6,046 | $10.76 | $65,054.96 | | |
| 4/29/2016 | Fmr Llc | Insider | Sell | 4,723 | $10.80 | $51,008.40 | | |
| 4/28/2016 | Fmr Llc | Insider | Sell | 33,196 | $11.23 | $372,791.08 | | |
| 4/26/2016 | Fmr Llc | Insider | Sell | 9,188 | $11.19 | $102,813.72 | | |
| 4/22/2016 | Fmr Llc | Insider | Sell | 20,558 | $11.30 | $232,305.40 | | |
| 4/20/2016 | Fmr Llc | Insider | Sell | 13,189 | $11.66 | $153,783.74 | | |
| 4/18/2016 | Fmr Llc | Insider | Sell | 18,900 | $11.75 | $222,075.00 | | |
| 4/14/2016 | Fmr Llc | Insider | Sell | 27,036 | $11.46 | $309,832.56 | | |
| 9/22/2015 | James E Flynn | Insider | Buy | 175,000 | $22.00 | $3,850,000.00 | | |
(Data available from 1/1/2013 forward)
REGENXBIO (NASDAQ RGNX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | REGENXBIO Inc. (RGNX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 18 at 3:48 AM |
| Insider Selling: REGENXBIO Inc. (RGNX) CFO Sells 7,500 Shares of Stock
www.americanbankingnews.com - May 16 at 7:50 PM |
| Donald J. Hayden, Jr. Sells 15,000 Shares of REGENXBIO Inc. (RGNX) Stock
www.americanbankingnews.com - May 16 at 7:32 PM |
| REGENXBIO (RGNX) Upgraded to "C" at TheStreet
www.americanbankingnews.com - May 15 at 1:06 PM |
 | REGENXBIO Joins the Mucopolysaccharidosis Community to Advance Research and Innovation
finance.yahoo.com - May 15 at 9:39 AM |
| Edited Transcript of RGNX earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 14 at 9:53 AM |
 | REGENXBIO's (RGNX) CEO Ken Mills on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 4:45 PM |
| REGENXBIO (RGNX) Upgraded to "Buy" at ValuEngine
www.americanbankingnews.com - May 11 at 9:23 PM |
 | RGNX Crosses Above Average Analyst Target
www.nasdaq.com - May 10 at 4:53 PM |
 | Regenxbio (RGNX) Tops Q1 EPS by 204c, Beats on Revenues
www.streetinsider.com - May 10 at 9:24 AM |
| Raymond James Reiterates $45.00 Price Target for REGENXBIO (RGNX)
www.americanbankingnews.com - May 9 at 5:12 PM |
| REGENXBIO to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference
finance.yahoo.com - May 9 at 4:44 PM |
| REGENXBIO (RGNX) Stock Rating Reaffirmed by Barclays
www.americanbankingnews.com - May 9 at 1:40 PM |
 | BRIEF-Regenxbio Reports Q1 Earnings Per Share $3.04
www.reuters.com - May 9 at 9:15 AM |
| Regenxbio: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:15 AM |
| REGENXBIO (RGNX) Issues Earnings Results, Beats Expectations By $1.06 EPS
www.americanbankingnews.com - May 8 at 8:14 PM |
| REGENXBIO Reports First Quarter 2018 Financial Results and Recent Operational Highlights
finance.yahoo.com - May 8 at 4:43 PM |
 | REGENXBIO Receives FDA Fast Track Designation for RGX-121 Gene Therapy for the Treatment of ...
www.prnewswire.com - May 2 at 9:09 AM |
| REGENXBIO Receives FDA Fast Track Designation for RGX-121 Gene Therapy for the Treatment of Mucopolysaccharidosis Type II
finance.yahoo.com - May 2 at 9:09 AM |
| REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2018 Financial Results and Recent ...
www.prnewswire.com - May 1 at 4:36 PM |
| REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2018 Financial Results and Recent Operational Highlights
finance.yahoo.com - May 1 at 4:36 PM |
| REGENXBIO (RGNX) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - April 30 at 8:34 AM |
| Critical Contrast: Denali Therapeutics (DNLI) versus REGENXBIO (RGNX)
www.americanbankingnews.com - April 24 at 9:31 PM |
| Insider Selling: REGENXBIO Inc. (RGNX) Insider Sells 10,000 Shares of Stock
www.americanbankingnews.com - April 24 at 7:32 PM |
| REGENXBIO Inc. (RGNX) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 23 at 3:34 AM |
| REGENXBIO (RGNX) Raised to "Buy" at BidaskClub
www.americanbankingnews.com - April 20 at 11:55 AM |
| Insider Selling: REGENXBIO Inc. (RGNX) CFO Sells 5,000 Shares of Stock
www.americanbankingnews.com - April 18 at 7:46 PM |
| Rounds Report: Regenxbio Surged Higher While Celldex Tumbled Due To A Negative Clinical Binary
seekingalpha.com - April 17 at 9:33 AM |
| REGENXBIO (RGNX) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - April 17 at 8:47 AM |
| Regenxbio Inc (RGNX) SVP Sells $390,000.00 in Stock
www.americanbankingnews.com - April 13 at 7:11 PM |
| How Analysts Rate Regenxbio and Peers in April 2018
finance.yahoo.com - April 13 at 4:42 PM |
| A Look at Regenxbio’s Recent Financial Performance
finance.yahoo.com - April 13 at 4:42 PM |
| What Investors Should Know about Regenxbio’s Research Pipeline
finance.yahoo.com - April 13 at 4:42 PM |
| How Regenxbio’s Cash Flows and Valuation Metrics Moved
finance.yahoo.com - April 13 at 4:42 PM |
| Chardan Capital Increases Regenxbio (RGNX) Price Target to $55.00
www.americanbankingnews.com - April 11 at 11:23 PM |
| Patrick J. Christmas Sells 10,000 Shares of Regenxbio Inc (RGNX) Stock
www.americanbankingnews.com - April 11 at 7:09 PM |
| Regenxbio (RGNX) Given a $45.00 Price Target at Raymond James Financial
www.americanbankingnews.com - April 11 at 6:13 PM |
| Regenxbio Inc. (RGNX) PT Raised to $29 at Mizuho Securities on $100M Milestone Related to NVX/AVXS
www.streetinsider.com - April 10 at 9:36 AM |
 | How a Rockville company benefits from Novartis' $8.7B purchase of a Chicago biotech
www.bizjournals.com - April 9 at 4:38 PM |
 | AVXS-101
www.benzinga.com - April 9 at 4:38 PM |
| Regenxbio (RGNX) PT Raised to $90.00
www.americanbankingnews.com - April 9 at 10:28 AM |
| REGENXBIO to receive $180M from NAV AAV9 licensee AveXis on Novartis tie-up; shares ahead 21% premarket
seekingalpha.com - April 9 at 9:25 AM |
| Regenxbio (RGNX) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - April 5 at 1:10 PM |
| Regenxbio (RGNX) Price Target Raised to $85.00 at Chardan Capital
www.americanbankingnews.com - March 31 at 7:10 PM |
| Regenxbio (RGNX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 30 at 2:18 PM |
| Regenxbio Inc (RGNX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 29 at 3:25 AM |
| Regenxbio Inc (RGNX) CFO Sells $150,000.00 in Stock
www.americanbankingnews.com - March 28 at 10:46 PM |
| Insider Selling: Regenxbio Inc (RGNX) Insider Sells 10,000 Shares of Stock
www.americanbankingnews.com - March 22 at 7:32 PM |
| Regenxbio (RGNX) Downgraded by BidaskClub to Hold
www.americanbankingnews.com - March 18 at 4:58 PM |
| Edited Transcript of RGNX earnings conference call or presentation 6-Mar-18 9:30pm GMT
finance.yahoo.com - March 18 at 9:08 AM |
REGENXBIO (NASDAQ:RGNX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
REGENXBIO (NASDAQ:RGNX) Income Statement, Balance Sheet and Cash Flow Statement
REGENXBIO (NASDAQ RGNX) Stock Chart for Sunday, May, 20, 2018
Loading chart…
